{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:03:38Z","timestamp":1764939818326,"version":"3.46.0"},"reference-count":7,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2025.2025.0216","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:14:16Z","timestamp":1753697656000},"source":"Crossref","is-referenced-by-count":0,"title":["Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra- High-Risk Relapsed\/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure"],"prefix":"10.4274","author":[{"given":"Bilal","family":"Kazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-ola","family":"Adallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imaan","family":"Rumani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzooka Nazim","family":"Chishti Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","unstructured":"1. Gagelmann N, Ayuk F, Atanackovic D, Kroger N. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis. Eur J Haematol. 2020;104:318-327.","journal-title":"Eur J Haematol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.blre.2023.101095","article-title":"Failure of CAR-T cell therapy in relapsed and re-fractory large cell lymphoma and multiple myeloma: an urgent unmet need","volume":"60","author":"St Martin","year":"2023","unstructured":"2. St Martin Y, Franz JK, Agha ME, Lazarus HM. Failure of CAR-T cell therapy in relapsed and re-fractory large cell lymphoma and multiple myeloma: an urgent unmet need. Blood Rev. 2023;60:101095.","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","unstructured":"3. Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Rich-ter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756-765.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41408-024-01197-2","article-title":"Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell thera-py","volume":"14","author":"Merz","year":"2024","unstructured":"4. Merz M, Dima D, Hashmi H, Ahmed N, St\u00f6lzel F, Holderried TAW, Fenk R, M\u00fcller F, Tovar N, Oliver-C\u00e1ldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kr\u00f6ger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell thera-py. Blood Cancer J. 2024;14:214.","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","unstructured":"5. Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sper-ling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with re-sponse and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","unstructured":"6. Fischer L, Grieb N, Born P, Weiss R, Seiffert S, Boldt A, Fricke S, Franz P, Heyn S, Kubasch AS, Baber R, Weidner H, Wang SY, Bach E, Hoffmann S, Ussmann J, Kirchberg J, Hell S, Schwind S, Metzeler KH, Herling M, Jentzsch M, Franke GN, Sack U, Reiche K, K\u00f6hl U, Platzbecker U, Vucinic V, Merz M. Cellular dynamics following CAR T cell therapy are associated with re-sponse and toxicity in relapsed\/refractory myeloma. Leukemia. 2024;38:372-382.","journal-title":"Leukemia"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","unstructured":"7. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wag-ner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","journal-title":"J Hematol Oncol"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:59:55Z","timestamp":1764939595000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-76032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":7,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2025.2025.0216","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}